with Leishmania donovani resulted in enhanced formation of granulomas and in vitro production of gamma interferon. By direct microscopical enumeration, reduction in gross parasite burden in the viscera was not observed, however. These data highlight an important discordance between granuloma formation per se and parasite elimination and suggest that interleukin-1 deficiency alone cannot account for the chronicity of this disease.
Evidence is now accumulating to suggest that resolution from infection with the intracellular parasite Leishmania donovani is dependent on the coordinated interactions between the components of the cell-mediated immune system. This includes the activation of helper and effector T-cell populations into appropriate cytokine production, the priming/activation of macrophages, and the continued maintenance of these interactions. These events culminate histologically in the granulomatous tissue reaction (17, 24-26, 34, 41) .
The cytokine interleukin-1 (IL-1) plays a pivotal role in host defense against microbial infection. It functions to provide important costimulatory signals during T-cell activation and may enhance class II expression on some antigenpresenting cells (11, 15, 20, 23, 29, 35, 40) . These events lead to enhanced T-cell production of cytokines such as IL-2 and gamma interferon (IFN-y). In addition, IL-1 is an important mediator of inflammation (10, 11, 21) and of the cellular influx involved in granuloma formation (1, 6, 11, 22 (3-5, 7-9, 28, 36, 37) .
Chronic infection with L. donovani is associated with T-cell nonresponsiveness towards both antigen and mitogens (19, 25, 27, 31) . In addition, our recent investigations have shown that splenic antigen-presenting cells isolated from infected animals have reduced capacity to support costimulator-dependent T-cell responses, e.g., to anti-CD3 (5a). Given the critical role of IL-1 in cell-mediated immunity, and that decreased IL-1 production has been associated with L. donovani infection of murine peritoneal and human peripheral blood monocyte populations in vitro (30, 32) , we have administered recombinant human IL-la (specific activity, 3 x 108 D10 units/mg; gift of P. Lomedico, Hoffman La Roche) in two different schedules to B1O.D2/n mice chronically infected with L. donovani.
Mice were infected via the lateral tail vein with L. donovani amastigotes as previously described (19) . Groups of mice were monitored over time to ensure that a stable level of chronic infection had been achieved. Two IL-1 administration schedules were adopted on the basis of previously published protocols. In the first, mice at 36 weeks of (17, 19) . Fever and rigor accompanied IL-la administration, as described by others (10, 11) . This subsided by 2 to 4 h in uninfected mice and by 24 h in infected mice. Uninfected mice showed both splenomegaly and hepatomegaly of approximately 30 to 40% at sacrifice, whereas those for infected mice were a further 15 to 20% above the enlargements already induced by infection (data not shown). This increase in organ weight probably reflects the capacity of this cytokine to induce cellular influx (11, 13) . Analysis of parasite burden in the spleen and liver in low-dose (Table 1 )-treated mice revealed that IL-la did not have any significant effect on disease course. This was also the case for animals given a high-dose regimen (log LDU of 3.33 + 0.2 and 2.05 ± 0.2 for livers and spleens, respectively, of untreated mice compared with 3.32 ± 0.3 and 2.36 + 0.2, respectively, for IL-1-treated mice).
Resolution from L. donovani infection has been associated with granuloma production (17, 24, 26, 42) . Paraffin sections of livers from high-dose-treated mice were therefore stained for the presence of Leishmania infection by using polyclonal antisera (raised in rabbits against L. donovani promastigote membranes) and immunoperoxidase and then counterstained with hematoxylin to reveal both parasite number and distribution and tissue responses (17) . The number of granulomas per 30 microscope fields (magnification, x400) as well as the number of parasites within and outside the granulomas was determined ( Table 2 and Fig. 1 ). Granulomas were readily detectable in the livers of infected mice, though some of these comprised less mature accumulations of inflammatory cells. Granuloma number increased significantly with IL-la administration, and, as importantly, there was also a dramatic change in the distribution of the parasites in relation to granulomas. IL-la treatment resulted in more than 74% of the parasites being localized within these structures compared with only 46% in the absence of IL-la. A similar augmentation of the granulomatous response by IL-1 was previously observed for experimental listeriosis (7-9). Granulomas were not induced by IL-la treatment of uninfected control mice.
Unlike cutaneous leishmaniasis (14) , chronic murine visceral leishmaniasis is associated with a lack of observable cytokine synthesis in vitro (19) . On the basis of this data, we have previously suggested that both Thl and Th2 populations may have entered a state of nonresponsiveness (18, 19) . Analysis of spleen cell populations from infected and IL-la-treated infected mice revealed that neither the proliferative nonresponsiveness nor the production of IL-2/IL-4 and IL-3 was restored by IL-la treatment. (In all cases, responses were compared with those of mice at 7 days of infection, which show positive proliferative and cytokine responses; data not shown). The low-dose IL-la schedule did, however, enhance antigen-dependent IFN-y production (1) or IL-la (0) were cultured in medium alone or with LPS for 48 h, and supernatant IL-1 levels were determined by bioassay using the D10.G41 cell line (16) . Values represent the mean counts per minute ± standard deviation for triplicate cultures.
in vitro (Fig. 2) . The level of IFN--y produced in these animals was still only approximately 20% of that routinely observed in major histocompatibility complex congenic strains of mice cured of infection (see reference 19 for comparisons). In contrast, high-dose IL-la treatment led to the spontaneous production of IFN--y (>2 ng/ml) and IL-5 (1.5 to 2 ng/ml) in all groups of animals, including uninfected controls. Addition of antigen did not enhance this production further (data not shown). This finding confirms previous data that under appropriate mitogenic stimuli both Thl and Th2 cytokines can be produced by spleen cell populations from both naive and these chronically infected animals (19) .
We also examined whether IL-la administration in vivo altered the capacity of spleen cells to produce IL-1 in vitro because of autocrine regulation (12, 39). Spleen cells were cultured in medium alone or in the presence of 10 pg of lipopolysaccharide (LPS, lot L4391; Sigma, Poole, United Kingdom) for 48 h, and the concentration of IL-1 was determined by using the D10.G4.1 cell line (16) . Our results (Fig. 3) demonstrate that IL-la in vivo had no effect on the subsequent capacity to produce IL-1 in vitro in response to LPS. Significantly, however, infected mice had a much higher spontaneous level of IL-1 production in vitro than their uninfected controls, a result which may indicate that some IL-1 could also be produced in vivo in these animals.
In summary, therefore, we have demonstrated that although IL-la administration in vivo enhances both the ability to form mature granulomas and IFN-y production in response to antigen in vitro, these combined effects do not lead to detectable enhancement of amastigote killing. Although this may reflect a quantitative deficiency in IFN--y, recent investigations by others (2, 33, 41) have suggested that IFN--y alone may be insufficient for inducing leishmanicidal activity, and the strategy we employed here may have failed to significantly augment these additional facets of the response. Dissecting these interactions within the granuloma remains an important future goal. Finally, the studies reported here for a murine model of visceral leishmaniasis demonstrate that IL-la treatment had little effect on the course of chronic disease. However, as there is only limited information on the immunological regulation of chronic human visceral leishmaniasis, the possibility remains that this cytokine may have an immunomodulatory function in humans.
